#United States #New York #Class Action #Lead Plaintiff #Gossamer Bio

Gross Law Firm Urges Shareholders to Take Action on Gossamer Bio Lawsuit

The Gross Law Firm has officially notified shareholders of Gossamer Bio, Inc. (traded on NASDAQ under the symbol GOSS) of an important deadline approaching on June 1, 2026. This serves as a reminder for individuals who purchased shares of GOSS during a specified class period to consider the opportunity to register for lead plaintiff status in a class action lawsuit against the company.

Background of the Case

The class period for this action is defined as being between June 16, 2025, and February 20, 2026. Allegations made in the complaint suggest that the defendants—key individuals representing Gossamer Bio—provided investors with overly optimistic statements concerning the company’s prospects. While promoting a positive outlook, it is asserted that they also concealed significant adverse facts regarding the study design of its Phase 3 clinical trial, known as the PROSERA study. A particular concern raised is the manner in which Gossamer handled the placebo response from participants at sites in Latin America.

On February 23, 2026, Gossamer released results from this Phase 3 study, revealing that it did not fulfill the primary endpoint of improved six-minute walk distance (6MWD) after a 24-week evaluation, achieving a mere +13.3 meter placebo-adjusted gain, which did not meet the critical statistical threshold of 0.025. Due to a population sample that was viewed as lower-risk and heavily treated, the company claimed it had been misled about the outcomes at those testing sites. The immediate aftermath saw Gossamer’s stock price plummet over 80%, falling from $2.13 to $0.42 within just a day.

Shareholder Actions

Shareholders who participated in purchasing shares during the mentioned timeframe are strongly encouraged to reach out to the Gross Law Firm for potential lead plaintiff appointments. Although taking on the lead plaintiff role is not necessary to recover any losses incurred, those interested in leading the charge against Gossamer are urged to act promptly. Interested shareholders can submit their information via the provided link for tracking their status and ensuring they receive updates as the case progresses.

The deadline for seeking lead plaintiff status is June 1, 2026, meaning shareholders should not hesitate to engage if they believe they have been wronged by the company's actions.

The Role of the Gross Law Firm

The Gross Law Firm is recognized across the nation for its unwavering dedication to safeguarding the rights of investors who have faced losses due to fraudulent or deceitful business practices. The firm remains committed to advocating for corporate accountability and ensuring companies follow fair and ethical business practices. They are particularly focused on recovering losses for investors arising from misleading statements or omissions that artificially inflated stock prices.

Conclusion

As the deadline approaches, it is crucial for shareholders of Gossamer Bio to stay informed and take the necessary steps to protect their interests. The Gross Law Firm stands ready to assist shareholders in navigating this complex situation, aiming to ensure every affected individual has the opportunity to pursue justice. To engage with the Gross Law Firm, you can contact them directly:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Act now to safeguard your rights and potentially secure compensation in this significant lawsuit.